Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.2900
-0.0051 (-1.73%)
At close: Aug 21, 2026, 4:00 PM EDT
0.2653
-0.0247 (-8.52%)
After-hours: Aug 21, 2026, 8:00 PM EDT
Kairos Pharma Employees
As of December 31, 2025, Kairos Pharma had 4 total employees, including 1 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,451,250
Market Cap
6.87M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 1 | 3 |
| Dec 31, 2024 | 4 | - | - | 1 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| Bolt Biotherapeutics | 23 |
| NuCana | 12 |
| Purple Biotech | 10 |
| Enveric Biosciences | 6 |
| Alzamend Neuro | 6 |
| XTL Biopharmaceuticals | 5 |
| Can-Fite BioPharma | 5 |
| Acurx Pharmaceuticals | 4 |
KAPA News
- 1 day ago - Kairos Pharma announces 1-for-7 reverse stock split - TheFly
- 1 day ago - Kairos Pharma Announces 1-for-7 Reverse Stock Split - Business Wire
- 11 days ago - Kairos Pharma Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Kairos Pharma announces collaboration with Bayer to enhance XOFIGO - TheFly
- 4 weeks ago - Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer - Business Wire
- 5 weeks ago - CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever - Newsfile Corp
- 5 weeks ago - Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105 - TheFly
- 5 weeks ago - Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market - Business Wire